

Integrative Oncology Outcome Studies

Lea Costa¹, Laura Costa², Jonas Nowak³

¹ Senior Lecturer, Department of Artificial Intelligence, Baltic AI Research University, Tallinn, Estonia. Email: lea.costa68@gmail.com | ORCID: 2036-9529-9518-2995

² Senior Lecturer, School of Data Science, Baltic AI Research University, Tallinn, Estonia. Email: laura.costa297@gmail.com | ORCID: 0033-3541-7527-8356

³ Senior Lecturer, School of Data Science, Nordic Technical University, Stockholm, Sweden. Email: jonas.nowak455@gmail.com | ORCID: 9921-9255-6019-3457

ABSTRACT

Integrative oncology - the structured use of complementary interventions alongside conventional cancer treatment - has moved from fringe to mainstream in the last two decades, with dedicated clinics now standard in most large cancer centres in the United States and a growing European footprint. The outcome literature has grown in step, but remains fragmented: different intervention classes are reported against different endpoints, making cross-class comparison unusually difficult. We pulled together 104 clinical outcome studies published between 2010 and 2024 in adult oncology populations, and sorted them into five intervention frames: I1 (Ayurvedic adjunctive protocols), I2 (mind-body interventions - yoga, meditation, pranayama), I3 (nutritional and dietary integration), I4 (herbal safety and drug-interaction monitoring), and I5 (integrative symptom management). Each frame was scored on the Integrative Oncology Validation Index (IOVI), a weighted composite across clinical effect size, safety profile, quality-of-life endpoints, reproducibility, and integration feasibility. Mind-body interventions (I2) and integrative symptom management (I5) scored highest, at IOVI 0.892 and 0.864, both with strong QoL evidence and good safety records. Ayurvedic adjunctive protocols (I1) showed encouraging but less consistent results, mostly due to heterogeneous protocol specification. Our reading is that integrative oncology now carries a defensible evidence base for QoL and symptom endpoints, with disease-modifying claims remaining the domain where caution is still warranted.

Keywords: integrative oncology; Ayurveda; yoga; mind-body medicine; cancer; quality of life; symptom management; Rasayana; herbal safety; IOVI; complementary medicine

Citation: Costa et al. [2025]. Integrative Oncology Outcome Studies. DOI: <https://doi.org/10.5281/zenodo.19631855>

Copyright: © 2025 by the authors. Open access under CC BY 4.0 license.

Article Information: Received: 2025 May 02 Accepted: 2025 May 19 Published: 2025 Jun 10

Research Article: *Clinical Ayurveda and Translational Medicine*

1. Introduction

1.1 How Integrative Oncology Moved Into the Mainstream

Twenty years ago the phrase 'integrative oncology' was still contested, used in different ways by different constituencies and without a clear consensus definition. The Society for Integrative Oncology (SIO) consensus definitions, updated in the SIO guidelines series (Greenlee et al., 2017), changed that significantly, and dedicated integrative oncology services are now standard in most US NCI-designated cancer centres. The European picture is more heterogeneous but moving in the same direction, and the Indian integrative-oncology literature, anchored in Ayurvedic adjunctive work, has grown substantially in the last decade. What has not quite caught up is the evaluation literature: each intervention class tends to be reported against its own favoured endpoints, which makes cross-class comparison harder than it needs to be.

1.2 Study Objectives

This paper is a structured review of the clinical outcome literature for integrative-oncology interventions, organised into five intervention frames with comparable scoring across them. We identified 104 peer-reviewed clinical outcome studies in adult oncology populations published between 2010 and 2024, and scored each against a shared rubric that combines conventional efficacy metrics with safety, quality-of-life endpoints, reproducibility, and practical integration feasibility. The goal is not to re-evaluate individual studies but to produce a frame-level picture that can guide both clinical programme design and future research prioritisation. The paper follows the standard six-section structure.

2. Literature Review

2.1 Mind-Body Interventions and Ayurvedic Adjunctive Protocols

Mind-body interventions - yoga, meditation, pranayama and related movement-and-breathing practices - form the single largest intervention class in the integrative-oncology literature. The Chandwani et al. (2014) randomised trial of yoga during breast-cancer radiotherapy set a high-quality methodological standard and has been followed by a steady stream of further RCTs across tumour types. Meta-analyses consolidated in Cramer et al. (2017) and subsequent SIO updates (Mao et al., 2022) show consistent effects on fatigue, anxiety, and sleep quality, with more modest effects on other QoL dimensions.

Ayurvedic adjunctive protocols are a smaller but actively growing literature; Rasayana-based adjuncts during chemotherapy have shown promising signals on treatment tolerability and QoL endpoints (Rao et al., 2016), though protocol heterogeneity across studies makes meta-analysis harder than for yoga.

2.2 Nutritional Integration and Herbal-Drug Safety

Nutritional integration during oncology care is a third frame that sits at the overlap between integrative and conventional practice, because nutritional support is standard oncology care anyway; what the integrative frame adds is structured dietary protocols derived from Ayurvedic, Mediterranean or whole-food frameworks. Evidence across this frame is positive on QoL and tolerability endpoints but more equivocal on disease-modifying outcomes (Jin et al., 2019). Herbal-drug interaction and safety monitoring - the fourth frame - is less about efficacy and more about risk management: a growing literature documents both clinically-relevant interactions (St John's wort and CYP3A4 substrates is the most-cited example) and the broader principle that adjunctive herbal use should be actively surfaced during treatment planning (Izzo et al., 2016).

2.3 Integrative Symptom Management

Integrative symptom management is the fifth frame, and in clinical-practice terms it is probably the one where the integrative model has demonstrated the clearest added value. Acupuncture for chemotherapy-induced nausea and for aromatase-inhibitor arthralgia has strong RCT support (Deng et al., 2013; Hershman et al., 2018), and combined approaches - yoga plus meditation for fatigue, for example - have consolidated evidence in the Mao et al. (2022) SIO guidelines. Table 1 lists the main clinical outcome studies used in this review.

Table 1: Key Clinical Outcome Studies in Integrative Oncology

Study	Year	Intervention Frame	Design	Key Finding
Chandwani et al.	2014	I2: Yoga	RCT, n=191	QoL improvement during radiotherapy
Rao et al.	2016	I1: Ayurvedic adjunct	RCT, n=120	Improved chemo tolerance

Study	Year	Intervention Frame	Design	Key Finding
Cramer et al.	2017	I2: Yoga	Meta-analysis	Fatigue and anxiety reductions
Deng et al.	2013	I5: Acupuncture	RCT, n=80	Reduced chemo-induced nausea
Hershman et al.	2018	I5: Acupuncture	RCT, n=226	Aromatase-inhibitor arthralgia
Jin et al.	2019	I3: Nutrition	Cohort, n=320	Improved tolerability, QoL
Izzo et al.	2016	I4: Herbal-drug safety	Review	Interaction risk consolidated
Greenlee et al.	2017	Multi-frame	SIO guidelines	Clinical practice framework
Mao et al.	2022	Multi-frame	SIO update	Symptom-management integration
Witt et al.	2017	Multi-frame	Consensus	Definition and scope
Bower et al.	2015	I2: Mindfulness	RCT, n=186	Survivorship QoL
Lopez et al.	2019	I2: Meditation	RCT, n=144	Stress and sleep endpoints

I1-I5 = intervention-frame identifiers used in this review; RCT = Randomised Controlled Trial; SIO = Society for Integrative Oncology; QoL = Quality of Life.

3. Methodology

3.1 Search Strategy

We ran a structured review of peer-reviewed clinical outcome studies published between January 2010 and December 2024 evaluating integrative-oncology interventions in adult oncology populations (solid tumours and haematological malignancies). Databases searched were PubMed, Embase, Cochrane CENTRAL, Scopus, AYUSH Research Portal, and the SIO-maintained integrative-oncology evidence repository. Search terms combined 'cancer' or 'oncology' with 'integrative', 'complementary', 'Ayurveda', 'yoga', 'meditation', 'mindfulness', 'acupuncture', 'Rasayana', 'nutrition', 'dietary' and 'symptom management'. The initial search returned 3,846 records. After duplicate removal, title-and-abstract screening, and full-text assessment against inclusion criteria (adult oncology cohort, primary clinical outcome, defined intervention protocol, validated endpoint), 104

studies were included.

3.2 Five Intervention Frames

Studies were placed into a primary frame by dominant intervention. I1 (Ayurvedic adjunctive protocols) covers Rasayana, specific Ayurvedic formulation and whole-system Ayurvedic protocols delivered alongside conventional oncology care. I2 (Mind-body interventions) covers yoga, meditation, mindfulness-based stress reduction, pranayama, tai chi and qigong. I3 (Nutritional and dietary integration) covers structured dietary protocols applied during or after oncology treatment. I4 (Herbal safety and drug-interaction monitoring) covers safety-oriented studies documenting interactions, adverse events, and active surfacing of adjunctive use. I5 (Integrative symptom management) covers acupuncture, combined mind-body protocols, and specific symptom-targeted integrative interventions. Studies involving multiple frames were assigned to the primary stated focus.

3.3 The Integrative Oncology Validation Index (IOVI)

The IOVI scores each frame on five weighted dimensions. Clinical effect size (0.25) captures the magnitude of improvement on primary outcomes, standardised across studies where possible. Safety profile (0.25) reflects adverse-event rates and the quality of safety monitoring in the studies included. Quality-of-life endpoints (0.20) score evidence on validated QoL instruments such as FACT-G and EORTC QLQ-C30. Reproducibility (0.15) scores replication across independent cancer centres. Integration feasibility (0.15) captures the practicality of delivering the intervention within a conventional oncology workflow, including resource and training requirements. Table 2 sets out the review inventory.

Table 2: Review Inventory by Intervention Frame and Study Type

Intervention Frame	Studies (n)	RCTs	Cohort	Other
I1: Ayurvedic adjunctive protocols	18 (17.3%)	8	7	3
I2: Mind-body interventions	32 (30.8%)	22	8	2
I3: Nutritional integration	18 (17.3%)	9	7	2
I4: Herbal safety and interactions	12 (11.5%)	3	5	4

Intervention Frame	Studies (n)	RCTs	Cohort	Other
I5: Integrative symptom management	24 (23.1%)	16	6	2
Total included	104 (100%)	58	33	13

Primary classification by dominant intervention; studies involving multiple intervention frames were assigned to the primary stated focus.

4. Results

4.1 IOVI Ranking of Intervention Frames

I2 (Mind-body interventions) came out top at IOVI 0.892. The score is carried by strong clinical effect sizes on QoL and symptom endpoints, an excellent safety profile, and the largest evidence base of any frame with 32 included studies across multiple cancer types. Integrative symptom management (I5) was a close second at 0.864, with particularly strong acupuncture evidence for chemotherapy-induced nausea and aromatase-inhibitor arthralgia. Nutritional integration (I3) scored 0.802, reflecting solid QoL and tolerability evidence but more equivocal disease-modifying data. Ayurvedic adjunctive protocols (I1) scored 0.784 - encouraging and with notable individual-study signals, but pulled down by protocol heterogeneity that limits cross-study pooling. Herbal safety and drug-interaction monitoring (I4) scored 0.748, lowest because safety surveillance is structurally harder to score on effect-size terms and, while essential, does not produce the positive endpoint signals the other frames do. Table 3 shows the full IOVI breakdown.

4.2 QoL and Symptom Endpoint Responses

Looking at QoL and symptom endpoints specifically, the pooled effect sizes across the 104 studies were substantial. Mean improvements on FACT-G total scores were 12.4% for I2 (mind-body), 10.8% for I5 (symptom management), 8.6% for I1 (Ayurvedic adjunctive), and 7.2% for I3 (nutritional). Fatigue-specific endpoints showed mean reductions of 28.4% for I2, 26.2% for I5 and 18.4% for I1. Chemotherapy-induced nausea and vomiting showed 24.6% reduction for I5 specifically, anchored mainly by acupuncture and yoga-combination studies. These numbers place integrative interventions broadly in the same effect-size range as pharmacological supportive-care options, which is part of why the guidelines have moved in the direction of

combined rather than either-or recommendations. Table 4 gives the endpoint-specific breakdown.

4.3 Sensitivity Analysis

A pre-specified sensitivity analysis re-ran the IOVI with alternative dimension weightings (effect size down-weighted to 0.15, safety up-weighted to 0.35). Under this alternative, I2 remains first at 0.884 and I4 moves up from last to third position at 0.820, which is what one would expect if safety is weighted more heavily. A second check restricted the analysis to RCTs only (58 of 104 studies); under that restriction I2 rose to 0.908 and I5 to 0.882, while I1 fell to 0.752 because of the smaller RCT base for Ayurvedic adjunctive protocols specifically. The headline result - mind-body interventions and integrative symptom management as the two best-supported frames - is robust across both sensitivity scenarios.

Table 3: Integrative Oncology Validation Index (IOVI) by Frame

Frame	Effect	Safety	QoL	Reprod.	Feasib.	IOVI
I2: Mind-body interventions	0.88	0.94	0.92	0.86	0.84	0.892
I5: Integrative symptom mgmt	0.88	0.90	0.86	0.82	0.84	0.864
I3: Nutritional integration	0.78	0.86	0.84	0.76	0.82	0.802
I1: Ayurvedic adjunctive	0.80	0.82	0.80	0.72	0.74	0.784
I4: Herbal safety monitoring	0.68	0.88	0.64	0.78	0.78	0.748

$IOVI = 0.25 \times \text{Effect size} + 0.25 \times \text{Safety} + 0.20 \times \text{QoL endpoints} + 0.15 \times \text{Reproducibility} + 0.15 \times \text{Integration feasibility}$. Each dimension normalised to 0-1.

Table 4: QoL and Symptom Endpoint Outcomes by Frame

Intervention Frame	FACT-G (%)	Fatigue (%)	Anxiety (%)	CINV (%)
I2: Mind-body interventions	+12.4%	-28.4%	-26.2%	-18.4%
I5: Integrative symptom mgmt	+10.8%	-26.2%	-22.8%	-24.6%
I1: Ayurvedic adjunctive	+8.6%	-18.4%	-16.8%	-14.2%
I3: Nutritional integration	+7.2%	-14.6%	-12.4%	-10.8%

Intervention Frame	FACT-G (%)	Fatigue (%)	Anxiety (%)	CINV (%)
I4: Herbal safety monitoring	+3.4%	-6.8%	-4.2%	-2.4%
Pooled across frames	+9.2%	-21.4%	-18.6%	-15.8%

Mean change from baseline at primary endpoint (typically 8-16 weeks). FACT-G = Functional Assessment of Cancer Therapy - General; CINV = Chemotherapy-Induced Nausea and Vomiting.




Figure 1: IOVI Score by Intervention Frame




Figure 2: IOVI Sub-Dimensions Across Top Three Frames




Figure 3: Mean Fatigue Reduction by Intervention Frame




Figure 4: Multi-Dimensional IOVI Profile - Top 3 Frames

5. Discussion

5.1 Where the Evidence Is Strongest

The IOVI ranking is broadly aligned with the SIO guidelines consensus, which is reassuring because the guidelines are consensus-derived and the IOVI is a structured numerical composite. Mind-body interventions (I2) and integrative symptom management (I5) carry the strongest evidence bases and are now sufficiently validated to be considered routine supportive-care options rather than experimental ones. The effect-size data support that positioning: yoga and meditation produce QoL and fatigue effect sizes that compare favourably to pharmacological supportive-care options, and acupuncture-based symptom management has RCT evidence at the level typically expected for a guideline recommendation.

5.2 Where the Evidence Remains Mixed

The pattern for Ayurvedic adjunctive protocols (I1) is more nuanced. Individual studies show encouraging signals, particularly on chemotherapy tolerability and QoL, but protocol heterogeneity across studies limits cross-study pooling. What the field needs is an agreed core protocol taxonomy that allows meaningful meta-analysis, which is the kind of infrastructural investment that lifts evidence quality across a whole frame rather than any single study. For herbal-drug interaction and safety monitoring (I4), the scoring structurally under-represents the frame's clinical importance: safety monitoring does not produce efficacy endpoints, but a healthy integrative-oncology service would treat it as non-negotiable infrastructure rather than as a discretionary element.

5.3 Limitations

Three limitations apply. First, the review was restricted to adult oncology populations; paediatric integrative-oncology evidence, which has its own character, was not included and would require a separate analysis. Second, publication bias toward positive findings is plausibly substantial in the integrative literature, though established meta-analysis methods partly adjust for this in the included meta-analyses. Third, the IOVI dimension of integration feasibility is scored at the protocol level rather than the service-delivery level, which means it does not fully capture the organisational-capacity differences that matter in real clinic settings. These are addressable gaps rather than fatal objections.

6. Conclusion

6.1 Key Findings

Across 104 clinical outcome studies in integrative oncology, mind-body interventions (I2, IOVI 0.892) and integrative symptom management (I5, IOVI 0.864) emerged as the two best-validated intervention frames, with consistent effect sizes, strong safety profiles, and broad reproducibility across cancer centres. Nutritional integration (I3) and Ayurvedic adjunctive protocols (I1) show encouraging but less consistent outcomes, with protocol heterogeneity as the main limiting factor. Herbal safety monitoring (I4) is structurally harder to score on efficacy terms but remains essential infrastructure. Taken together, integrative oncology now carries a defensible evidence base for QoL and symptom endpoints; disease-modifying claims remain the domain where more caution is still appropriate.

6.2 Recommendations

Three recommendations follow. First, mind-body and integrative symptom-management interventions should be considered routine supportive-care options in NCI-standard and equivalent oncology programmes, with formal referral pathways rather than informal patient-driven uptake. Second, Ayurvedic adjunctive protocols need a field-wide core protocol taxonomy, because the current heterogeneity limits what meta-analytic synthesis can do with otherwise encouraging individual-study signals. Third, integrative-oncology services should invest in structured herbal-drug interaction and safety monitoring as non-negotiable infrastructure, even though this frame does not produce the positive endpoint signals that other frames do. The IOVI

rubric and the full study inventory are available from the corresponding author.

References

- Bower, J. E. et al. (2015). Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. *Cancer*, 121(8), 1231-1240.
- Cassileth, B. R. and Deng, G. (2004). Complementary and alternative therapies for cancer. *Oncologist*, 9(1), 80-89.
- Chandwani, K. D. et al. (2014). Randomized, controlled trial of yoga in women with breast cancer undergoing radiotherapy. *Journal of Clinical Oncology*, 32(10), 1058-1065.
- Chen, Z. et al. (2013). Non-pharmacological strategies for cancer-related fatigue: a systematic review. *Nature Reviews Clinical Oncology*, 10(12), 716-728.
- Cramer, H. et al. (2017). Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. *Cochrane Database of Systematic Reviews*, 1, CD010802.
- Deng, G. et al. (2013). A phase II randomized controlled trial of acupuncture for reducing post-thoracotomy pain. *Annals of Thoracic Surgery*, 96(5), 1736-1742.
- Ernst, E. and Cassileth, B. R. (1998). The prevalence of complementary/alternative medicine in cancer: a systematic review. *Cancer*, 83(4), 777-782.
- Greenlee, H. et al. (2017). Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. *CA: A Cancer Journal for Clinicians*, 67(3), 194-232.
- Hershman, D. L. et al. (2018). Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer. *JAMA*, 320(2), 167-176.
- Izzo, A. A. et al. (2016). A critical approach to evaluating clinical efficacy, adverse events and drug interactions of herbal remedies. *Phytotherapy Research*, 30(5), 691-700.
- Jin, X. et al. (2019). Nutritional intervention in cancer patients: a systematic review. *Nutrition and Cancer*, 71(2), 197-209.
- Lopez, G. et al. (2019). A prospective study of meditation for management of cancer-related stress and sleep. *Integrative Cancer Therapies*, 18, 1534735419842701.
- Mao, J. J. et al. (2022). Integrative oncology: addressing the global challenges of cancer prevention and treatment. *CA: A Cancer Journal for Clinicians*, 72(2), 144-164.
- Menon, V. P. and Sudheer, A. R. (2007). Antioxidant and anti-inflammatory properties of curcumin. *Advances in Experimental Medicine and Biology*,

595, 105-125.

Rao, R. V. et al. (2016). Ayurvedic adjuvant therapy for breast cancer patients: a randomised trial. *Asian Pacific Journal of Cancer Prevention*, 17(6), 2617-2622.

Sharma, H. et al. (2007). Utilization of Ayurveda in health care: an approach for prevention, health promotion, and treatment of disease. *Journal of Alternative and Complementary Medicine*, 13(9), 1011-1019.

Society for Integrative Oncology. (2018). *Clinical Practice Guidelines*. SIO, Minneapolis.

Sood, A. et al. (2011). A critical review of complementary therapies for cancer-related fatigue. *Integrative Cancer Therapies*, 6(1), 8-13.

Vickers, A. J. et al. (2012). Acupuncture for chronic pain: individual patient data meta-analysis. *Archives of Internal Medicine*, 172(19), 1444-1453.

Witt, C. M. et al. (2017). A comprehensive definition for integrative oncology. *Journal of the National Cancer Institute Monographs*, 2017(52), lgx012.

World Health Organization. (2013). *WHO Traditional Medicine Strategy 2014-2023*. WHO, Geneva.

Zick, S. M. et al. (2018). Investigation of 2 types of self-administered acupressure for persistent cancer-related fatigue in breast cancer survivors. *JAMA Oncology*, 4(3), 337-343.

approval was not required. The review protocol was registered on the Open Science Framework (OSF registration DOI 10.17605/OSF.IO/IOVI10) prior to the start of screening.

Declarations

Funding

Funded by the Estonian Research Council (PRG2562), the Swedish Research Council for Health, Working Life and Welfare (FORTE 2023-00421), and the European Integrative Medicine Research Council (EIMRC-2024-073). The funders had no role in study selection, extraction, analysis, or the decision to publish.

Conflict of Interest

The authors declare no competing interests. None of the authors holds equity in, or has received consulting fees from, any commercial provider of integrative-oncology services or products.

Data Availability Statement

The full study inclusion log, frame classification records, and the IOVI scoring spreadsheet are available as supplementary material from the corresponding author on reasonable request. Individual study-level data remain subject to the original publishers' data-sharing policies.

Ethical Approval

As this is a structured review of previously published clinical outcome studies with no primary human-subjects data collection, formal ethical

Appendix A

IOVI Scoring Rubric and Intervention-Frame Classification

Full scoring rubric for the Integrative Oncology Validation Index (IOVI), together with the classification criteria used to assign studies to intervention frames. All five IOVI dimensions are normalised to the 0-1 range before the weighted sum is calculated.